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Abstract
The aim of this study is to estimate the influence of polyphenolic compounds, renin inhibitors 
(Aliskiren) and their association on clinical and biochemical parameters, on an experimen-
tal model of arterial hypertension (AHT). The combination of Aliskiren and polyphenolic 
extract has the effect of reducing systolic and diastolic blood pressure. Experimental data 
highlight the hypocholesterolemic, antiatheromatous, hypolipidemic and cardioprotective 
effects of polyphenolic extracts. The results demonstrate a significant decrease in the mea-
sured biochemical parameters of the oxidative stress (unspecific - ceruloplasmin, uric acid 
and enzyme - GSH-Px and SOD) of the groups treated with polyphenolic extracts. In the 
polyphenolically protected AHT group there are statistically significant differences com-
pared to the AHT group, regarding the platelet adhesion index. Aliskiren has more evident 
vascular protective effects when associated with polyphenols in the experimental AHT 
compared to unprotected hypertensive group. The antioxidant properties of anthocyanins, 
combined with the vascular properties of these substances, recommend them as promising 
therapeutic agents in the prevention/therapy of cardiovascular disorders in general and of 
AHT in particular. The characterization of polyphenolic extracts, as well as the studies on 
biocompatibility, will constitute the baseline for understanding the mechanisms, by which 
phytopreparations can be used for preventive or adjuvant therapeutic purposes.
Keywords: systolic and diastolic blood pressure, aliskiren, polyphenolic extract, 
oxidative stress, lipid profile
1. Introduction
Hypertension, the most common cardiovascular disease, is the primary cause of stroke, coro-
nary artery disease and sudden cardiac death. Hypertension, a major public health issue, is a 
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multifactorial disease dependent on complex interactions between genetic and environmental 
factors, yet many of these causes are not completely understood. Although there is a wide 
range of hypertension drugs available, a number of new antihypertensive drugs have been 
introduced during the last two decades. [1].
The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in the homeostatic 
regulation of blood pressure, fluid electrolytic balance, tissue perfusion and vascular growth. 
Pharmacologic blockade of the RAAS has proven to be an effective therapeutic strategy in 
the treatment of several cardiovascular disorders, including hypertension [2]. ACE inhibitors 
(ACEIs), which block the conversion of Ang I to Ang II, angiotensin receptor blockers (ARBs), 
which interfere with the Ang II binding to its type 1 receptors [3] and aldosterone antago-
nists, which inhibit the aldosterone action via the mineralocorticoid receptor (MR) receptor 
are considered RAAS-inhibiting drugs in clinical practice. Nonetheless, these agents do not 
allow the complete RAAS suppression since the negative feedback effect of Ang II on renin 
release is disrupted and consequently, the plasma renin activity and reactive activation of the 
RAAS increase.
Renin-like enzymes, such as cathepsin D or tonins, which occur in the vascular wall and 
release angiotensin I from angiotensinogen, are not blocked by renin inhibitors [4].
Aliskiren is the first direct orally active renin inhibitor [5, 6]. It is an effective hypertension 
drug with specific characteristics, among which we should mention its good renin-angioten-
sin system blocking ability, its long-lasting action, its pharmacological effects that outlive 
drug discontinuation and its positive tolerability as compared to placebo [7, 8]. The antihy-
pertensive effect of aliskiren administered alone is similar or even better than that of other 
first-line hypertension agents. Moreover, its effect is considerably enhanced in combination 
with various other antihypertensive drugs and there are no adverse drug interactions [9–12]. 
Aliskiren is an extremely potent competitive inhibitor of renin. It has a high specificity for 
primate renin. This high specificity for renin makes it unlikely to produce adverse effects 
through interaction with other enzymes [13, 14].
Treatment of hypertension depends on the etiology of the disease and includes diet altera-
tions, weight loss, exercise and pharmacological interventions. Pharmacological therapies 
(e.g., renin inhibitors, ACEIs, diuretics) that exist to treat hypertension are successful but they 
may be associated with negative side effects such as persistent cough, dry throat, allergic 
reactions, dizziness, angioedema and kidney failure. The popularity of nutraceuticals, which 
is another name for dietary supplements, has increased in hypertension treatment and pre-
vention [15].
In addition to their high vitamin and fiber content, edible plants are also valuable since they 
are rich in polyphenols, which are antioxidant compounds responsible for some of the plants’ 
color, flavor and healing qualities [16].
Phytodrugs having a complex composition develop superior qualitative effects compared to 
the drugs which specify the synthetic and semisynthetic chemicals. Some natural antioxi-
dants, such as alkaloids, lycopene, phenolics, vitamin A/C/E, lipoic acid, and so on, are known 
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to provide oxidation protection to biological components (e.g., DNA, proteins, lipids, etc.). 
In cardiovascular disease, neurodegeneration, inflammation, aging, metabolic syndrome and 
others, the level of oxidative stress is increased [17].
Natural polyphenols, obtained from many plants, have been shown to exert important actions 
on the cardiovascular system and may be a potential source of new compounds to treat car-
diovascular diseases [18–21]. Observational evidence to date indicates that polyphenol-rich 
foods, in particular berries and dark chocolates, may influence cardiovascular disease risk fac-
tors [22–24]. The Sambucus nigra L. (elderberry) fruit extract is considered to be rich in primary 
polyphenols, leading to its high biological value [25].
2. The biochemical modifications of S. nigra extract on experimental 
arterial hypertension model
The French paradox undoubtedly emphasizes the effects of polyphenolics [17, 26], known 
as antioxidants, AMPK activator, ACE inhibitor and bioactive phytochemicals as they have 
many other biological benefits in addition to cardioprotection.
Scientists researching the medicinal benefits of the black elderberry plant have focused their 
work on the European species, S. nigra. The dark purple-black berries produced by this 
plant are rich in phytonutrients. It contains nearly four times the anthocyanins as compared 
to other commonly consumed berries. Elderberries are reported to include several bioactive 
compounds, both phenolic compounds like anthocyanin derivatives, including cyanidin 3-glu-
coside, cyanidin 3-sambubioside, cyanidin 3-sambubioside-5-glucoside and cyanidin 3,5-diglu-
coside [27–29] and triterpenic compounds such as ursolic and oleanolic acids and sterols such 
as β-sitosterol [30, 31].
2.1. The study of vascular reactivity by preliminary tests on the effects of a 
polyphenolic extract on in vitro isolated arterial fragments
Anthocyanins and some flavone (apigenin) and flavan-3-ol compounds may contribute to the 
prevention of hypertension. These vasodilatory properties may result from specific structural 
similarities (including the B-ring hydroxylation and methoxylation pattern) [32].
Polyphenol-rich extracts from fruits of S. nigra attenuate endothelial dysfunction induced by 
oxidative stress in mesenteric resistance arteries of rats.
Endothelial dysfunction, defined as the impairment of the endothelial-dependent relax-
ation by decreasing the nitric oxide (NO) bioavailability of endothelial origin, occurs 
through various mechanisms and is present in many pathological situations, and oxida-
tive stress is often a major component of the pathogen mechanism, especially due to the 
fact that NO is inactivated by a reaction with various highly reactive molecular species 
containing oxygen (free radicals). The vasodilatory and antioxidant effects of polyphenols 
from various plant sources are well-known but there are relatively few in vitro studies 
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concerning their influence on vascular reactivity and endothelial dysfunction induced by 
oxidative stress [33–35].
Anthocyanins are powerful antioxidants that are found in significant amounts in the extracts 
that we investigate and may be responsible for the protective action observed in vitro [36–38].
Dried and powdered elder fruits (50 g) were extracted with 2 × 250 ml acidulated methanol 
(0.5% HCl) using a magnetic stirrer, each time for 1 h. The total phenolic content in elder 
fruit extract was determined by the Singleton and Rossi method [39]. The amount of total 
phenolic content was expressed as g gallic acid equivalents (GAE)/100 g extract. The result is 
the mean of triplicates ± standard deviation. The absorbance levels of all the solutions were 
determined by means of a UV–VIS Able Jasco V-550 spectrophotometer.
We used isometric myography to study the fragments of the first-order branches of the mes-
enteric artery from the rat. Endothelial dysfunction was induced by incubation for 15 minutes 
with 0.4 mM pyrogallol with or without the concomitant presence of the polyphenol-rich 
extract. All substances, including extracts obtained from the S. nigra fruit (SAMB), were 
administered in the organ bath (5 ml) as small volumes of stock solutions (50 μl). For the 
evaluation of the antioxidant effect, we used the primary stock solution (50 mg extract per ml 
DMSO), administered in 1/100 dilution in the organ bath; this is also the maximum dose used 
in other tests related to vascular reactivity.
We examined the protector potential of the studied extracts in terms of endothelial dys-
function induced through acute oxidative stress in isolated resistance arteries from rats 
(Figure 1).
The obtained results highlight the effects of the studied extracts on vascular reactivity, specifi-
cally following antioxidant protection in vitro and assessing according to its ability to attenu-
ate the endothelial dysfunction induced by pyrogallol.
An immunohistochemical study performed by Kawa et al. [40] revealed that quercetin-3-O-
glucuronide, one of the main quercetin metabolites in the circulatory system, accumulates in 
macrophage-derived foam cells of human atherosclerotic lesions but not in the normal aorta. 
It is still difficult to say whether some polyphenols accumulate in specific target organs; prob-
ably, the endothelium is likely to be one of the primary sites of flavonoid action.
2.2. Effects of polyphenolic extract, renin inhibitors and their association in arterial 
hypertension induced by deoxycorticosterone acetate (DOCA)-salt
S. nigra extract contains 6.9 ± 0.3% g polyphenols and 290.72 ± 4.02% mg anthocyanins besides 
other compounds. The dry polyphenol extract was diluted in 100 ml polyphenolic solution 
containing 840 mg natural polyphenols, 95 ml distilled water and 5 ml DMSO. The experi-
ment used active therapeutic doses, well-determined fractions of DL50 on an experimental 
model of arterial hypertension.
Current preclinical studies were done on arterial hypertension models induced by DOCA-salt 
(deoxycorticosterone acetate-salt).
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2.2.1. The monitoring of heart rate, systolic and diastolic blood pressure
The monitoring of heart rate, systolic and diastolic blood pressure in the arterial hypertension 
experimental model was carried out with the CODA™ noninvasive blood pressure system 
[41] on white Wistar rats. American Heart Association (AHA) also recommends this method 
in its blood pressure measuring guide for laboratory animals. The actual experiment consists 
of carrying out at least six blood pressure measurements in each laboratory animal. The data 
collected should then be stored and processed using the CODA™ software.
The experiment was performed on the arterial hypertension model. The study was conducted on 
white Wistar rats with an average weight of 250–280 g, which were grouped in 6 groups of 
12 (Table 1).
According to the provisions of the Federation for Laboratory Animal Science Associations on 
working with laboratory animals, all the rats were kept in 12 h light/12 h dark conditions with 
free access to water and food.
In the first stage, the Shapiro-Wilk test was done to confirm the normality of the specimens (groups); 
this was considered positive on exceeding the materiality threshold of 0.05 (if p > 0.05). Then the 
descriptive statistics were done for each group, including the box-and-whisker plots.
Aliskiren, which acts in limited steps against the RAAS, is a logical component in the mixed 
therapy because it increases the suppression of the RAAS and alleviates the reactive increase of 
the plasmatic renin activity when it is added to other antihypertensive agent classes. The mixed 
inhibition of RAAS might allow the usage of smaller doses of each component for obtaining a 
Figure 1. The carbazole-induced endothelium-dependent relaxant effect (CTRL) in the first-order branches from the 
mesenteric artery of the rat is inhibited by pretreatment with 0.4 mM pyrogallol (OXID) and is not altered by pretreatment 
with 0.5 mg/ml extract of S. nigra fruit (SAMB, p > 0.05). This extract attenuates the pyrogallol-induced endothelial 
dysfunction (SAOX; * p < 0.01 vs. OXID). N = 4 in all series; student test for grouped values.
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more efficient and more sustainable suppression of RAAS and probably with less side effects 
[16, 42].
Using the direct renin suppressor in the mixed therapy with polyphenolic S. nigra extract 
assures an enhanced protection and improves the results compared to monotherapy. The 
electrocardiographic aspect is significantly improved in the hypertensive group protected 
with polyphenols compared to the unprotected hypertensive group.
Experimental data indicate the fact that the polyphenol-rich extract is capable not only to 
effectively slow down the evolution of hypertension in the AHT experimental model but also 
to normalize the blood pressure levels in the group which received S. nigra extract, respec-
tively, AHT + PS and AHT + Alisk + PS. The separate association of renin inhibitor and poly-
phenols in the hypertensive group reveals an improvement of the medium systolic blood 
pressure compared to the values obtained in the group which only received aliskiren. Similar 
data have been obtained for the diastolic component of blood pressure as well (Figure 2).
2.2.2. Biochemical plasma determinations (lipid profile, ceruloplasmin, uric acid and 
fibrinogen)
Polyphenol-induced AMPK activation suppresses lipogenic transcription factors (e.g., SREBP1/2, 
C/REBP, etc.) and enzymes (e.g., HMG-CoA reductase, acetyl-CoA carboxylase, etc.) for de novo 
biosyntheses of cholesterol and fatty acids and TG formation [43, 44].
In our study, the data underlined the fact that the lowest medium values of total cholesterol 
were recorded in hypertensive groups which received polyphenols (S. nigra) in addition to 
the renin inhibitor (aliskiren) (Figure 3a). Moreover, in order to support the lipid lowering 
effect of polyphenols, the mean triglyceride values detected were also lower in the groups 
which received S. nigra.
Due to the protection provided by polyphenols to the rats in the group AHT + PS, the LDL 
serum level is reduced, approaching the normal limits. Polyphenols have an important 
Group W Control group, contained normal animals, that did not receive natural polyphenols
Group PS Animals that were administered polyphenols under the form of solution, from the 
extract obtained from the S. nigra fruit, with a dosage of 0.045 g/Kg bw, p.o. (by 
tube feeding), at every 2 days for 4 weeks;
Group AHT Animals that were given s.c. DOCA-salt 20 mg/kg twice a week and NaCl (1%) 
added to the drinking water for 4 weeks
Group AHT + PS Animals that were given polyphenols PS in the mentioned dosage at every 2 days 
p.o., together with DOCA-salt for 4 weeks
Group AHT + Alisk Animals with AHT DOCA-induced that were given s.c. aliskiren 30 mg/Kg bw/day 
for 4 weeks
Group AHT + Alisk + PS Animals with hypertension (AHT) that were given DOCA-salt and PS polyphenols 
in the dosage mentioned for 4 weeks
Table 1. Groups used in experimental model.
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antiatherogenic role by their lipid lowering effect, especially by decreasing the synthesis 
and secretion of LDL and VLDL. In our study, HDL has significantly low values in the 
AHT group of rats compared to the rats in the W group and in the AHT + Alisk + PS group 
(Figure 3b).
Plasma proteins with high-molecular weight, such as ceruloplasmin, fibrinogen and 
C-reactive protein, have a powerful effect on red cell aggregation, a phenomenon found 
in hypertensive animals. In the experimental model we studied, the fact that the medium 
values of ceruloplasmin are higher in the other groups compared to the AHT group is to 
be noted, which suggests the beneficial antiradical effect of ceruloplasmin. S. nigra extract 
administration proved to be the most efficient, which determines the mean ceruloplas-
min values close to those recorded with the control. By stimulating the ceruloplasmin 
activity, the effect of the polyphenols is favorable, proving their additional antioxidant 
role [45, 46].
Figure 2. (a) The box-and-whisker plot of systolic blood pressure and (b) the box-and-whisker plot of diastolic blood 
pressure.
Figure 3. (a) The box-and-whisker plot of total cholesterol and (b) the box-and-whisker plot of HDL-cholesterol.
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The increase in the fibrinogen level generates modifications of the rheologic properties of the 
blood such as increased plasma viscosity, red cell aggregation, platelet thrombosis, alterations 
of the vascular reactivity and compromised endothelial integrity. The increase of fibrinogen 
concentration determines an increase of blood viscosity, which generates emphasized shear 
stress that activates endothelial cells and platelets. Thus, in our study, the highest mean val-
ues of fibrinogen are recorded in the AHT group, significantly higher than the other groups 
as well as fibrinogen-associated higher lipidic profile and heart rate.
Uric acid acts like a free radical scavenger due to the covalent bonds it can establish with the 
singlet oxygen. In animal models, hyperuricemia predisposes to high blood pressure by dif-
ferent mechanisms such as endothelial dysfunction, inflammation and vascular modifications 
at the renal microcirculation level, activation of the system renin-angiotensin-aldosterone. 
The data in our study is in line with that provided by the study [47], thus, the highest serum 
levels of the uric acid being registered in the hypertensive group. The lowest mean values of 
the uric acid are recorded in the groups treated with S. nigra and in the control group, signifi-
cantly lower compared to those recorded in the other investigated groups.
2.2.3. Enzymatic determinations (SOD, CAT, GSH-Px) and nonenzymatic ones (GSH) 
regarding the antioxidant capacity
Antioxidative stress is mainly achieved by the classical antioxidation, which is also ensured 
by ACE inhibition interrupting AT-II-induced ROS generation and by the anti-inflammatory 
actions blocking inflammation-oxidation axis. The mechanisms involved in the antioxi-
dant capacity of polyphenols include suppression of ROS formation by either inhibition of 
enzymes involved in their production, scavenging of ROS or upregulation or protection of 
antioxidant defenses [25, 48].
Polyphenol administration may offer indirect antioxidant protection by activating the endo-
gen defensive systems and by modulating the cellular signaling processes such as NF-kB 
activation, glutathione biosynthesis and MAPK proteins [49]. The mechanism of polyphenols 
on vascular function depends on the ability of nitric oxide synthase (eNOS) and its bioavail-
ability to the endothelium. This vascular nitric oxide regularity mechanism is believed to have 
involvement of polyphenols with kinase molecular signaling like PI3-kinase/Akt pathway and 
intracellular Ca2+ on eNOS phosphorylation which ultimately results in NO production [50].
Reduced glutathione (GSH) is an intracellular thiol antioxidant; lower level of this GSH 
causes higher ROS production, which results in imbalanced immune response, inflammation 
and susceptibility to infection [51].
GSH regeneration is provided by the enzymes in the pentose-phosphoric shunt, generator of 
NADPH (Zn-enzyme). GSH reacts with a wide variety of free radicals, having a free radical 
“scavenger” function and it contributes to the repair of the biologic disturbances mediated by 
radicals [52] (Figure 4). We did not record significant modifications regarding serum values of 
CAT in the AHT + PS, AHT + Alisk and AHT + Alisk + PS groups, compared to the control group.
The more the effects represent the total of their combined action, the more efficient is the activ-
ity of the antioxidants, each of them functioning according to different mechanisms and at 
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various levels of the free radical evolution link in the organism. As a result, polyphenols have 
the possibility of adjusting and limiting the free radical or reactive species (peroxide) excess [53].
The results obtained following statistical analysis prove a significant modification of the mea-
sured biochemical parameters of the oxidative stress (nonspecific—ceruloplasmin and uric 
acid and enzymatic—GSH-Px and SOD) in the sense of decreasing oxidative stress in the one 
which was administered S. nigra extract.
When the AHT group was under polyphenol and aliskiren protection (the AHT + Alisk + PS 
group), the serum activity of SOD returned to normal values. As a result of the oxidative 
stress in the AHT group, serum activity of SOD has significantly lower values (p < 0.001) com-
pared to those recorded with the W, AHT + PS and AHT + Alisk groups. We noticed that due 
to protection, the serum activity in the AHT + Alisk + PS group rats is more intense than in 
the case of the nonprotected AHT group (Figure 5). It should also be noted that, in the AHT 
group, low SOD values were noticed in association with low levels of ceruloplasmin and 
elevated levels of uric acid and fibrinogen.
Regardless of their antioxidant effect, polyphenols increase the production of vasodilator 
factors (NO, EDHF, prostacyclin) and inhibit the endothelin-1 synthesis with vasoconstric-
tor effect in the endothelial cells. Furthermore, it inhibits the expression of two major proan-
giogenic factors such as vascular endothelial growth factor (VEGF) and MMP-2 in smooth 
muscle cells.
Figure 4. The box-and-whisker plot of GSH.
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The changes in the redox status of the cell are determined by the endothelial dysfunction. 
Starting from previous studies that have discussed the potential antioxidant extract of S. nigra 
is proved that incorporation of anthocyanins from these fruits into endothelial cells causes 
protective effect against oxidative stress [54].
2.2.4. Platelet adhesion index determination
Activation of platelets adhering to the vascular endothelium induces the formation of lipid 
peroxidation and oxygen free radicals, which will inhibit synthesis of endothelial prostacy-
clins and NO. The effect of polyphenols in decreasing platelet activity has a strong impact on 
cardiovascular disease and can explain the epidemiological data on polyphenol function in 
cardiovascular disease [55, 56].
The main mechanisms by which flavonoids inhibit the platelet aggregation are: inhibition of 
phosphodiesterase with intracellular cAMP increase, cytoplasmic calcium reduction, cycloox-
ygenase inhibition, the enzyme involved in the transformation of arachidonic acid into TxA2, 
which is an aggregator and powerful vasoconstrictor [55]. In the AHT + PS group, there are 
statistically significant differences compared to the AHT group as well as to the control group 
(Figure 6). Platelet adhesion index (PAI) has been consistently correlated with the MDA level 
from the erythrocyte. Thus, there is a significant correlation between the intensity of the oxi-
dative stress and the supplementation with the polyphenolic extract.
Figure 5. The box-and-whisker plot of SOD.
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The antioxidant properties of anthocyanins, combined with the vascular properties, charac-
teristic of these substances, recommend it as promising therapeutic agents in the prevention/
therapy of cardiovascular diseases in general and of AHT in particular.
Natural polyphenols and aliskiren may influence enzymatic and nonenzymatic changes in 
experimental arterial hypertension, in the sense of their favorable evolution, by improving 
lipid alterations and oxidative stress.
The potential cardioprotective properties of S. nigra extract include mainly antihypertensive, 
antiatherogenic and anti-inflammatory activities as well as inhibition of the platelet activation 
and aggregation, and attenuation of endothelial dysfunction. The main antihypertensive effects 
are the increase in NO bioactivity, the reduction of endothelin-1 and the decrease in ACE.
The obtained results show that antioxidant activity is all the more intense, as the polyphenolic 
preparation is administered for a long time during the course of the disease. Ensuring a diet 
rich in anthocyanins has beneficial effects on the whole body, the assumption being sup-
ported by the experimental data that highlight the hypocholesterolemic, antiatheromatosus, 
hypolipidemic and cardioprotective effects of polyphenolic extracts.
Mechanistically, it has been suggested that dietary polyphenols can alleviate hypertension 
through anti-inflammatory and antioxidant effects and increased oxide nitric (NO) production 
[16]. The anti-inflammatory effect is associated with a reduced expression of the redox-sensitive 
Figure 6. The box-and-whisker plot of platelet adhesion index.
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nuclear factor-kB (NF-kB), while that the antioxidant effect of polyphenols is related to improved 
enzymatic activities of superoxide dismutase, catalase and glutathione peroxidase. In addition, 
polyphenols participate in the activation of the redox-sensitive phosphoinositide3 (PI3)-kinase/
Akt pathway, leading to increased formation of NO [16]. Taken together, all these pathways 
help to reduce blood pressure in hypertensive conditions.
The dynamics of international scientific research on hypertension and on its complications 
materialized in the creation of preparations with a wide range of action and variable side 
effects, which require further investigations. These preparations are designed to have the 
widest possible action range, both as concerns their main action and as concerns their pleio-
tropic effects.
3. Conclusions
Subsequent studies will explore the potential of the direct renin inhibitors/(pro)renin blockers 
both in monotherapy and in combination with antihypertensive drugs of other classes, as well 
as their use not only to reduce arterial pressure but also for their renal and cardioprotective 
effects. In this respect, the characterization of polyphenolic extracts, as well as the studies on 
their bioavailability and biocompatibility, will constitute the baseline for understanding the 
mechanisms by which phytopreparations can be used for preventive or adjuvant therapeutic 
purposes.
By carefully extrapolating the experimental findings on animals to humans, the study could 
contribute to the increase of the life expectancy of hypertension patients and to the improve-
ment of the life quality of the patients suffering from cardiovascular conditions.
Author details
Manuela Ciocoiu1*, Bogdan Mihail Diaconescu1 and Codruta Badescu2
*Address all correspondence to: mciocoiu2003@yahoo.com
1 Department of Pathophysiology, University of Medicine and Pharmacy “Grigore T. Popa”, 
Iasi, Romania
2 Internal Medicine Clinic, St. Spiridon Hospital, University of Medicine and Pharmacy 
“Grigore T. Popa”, Iasi, Romania
References
[1] James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfab C, Handler J, 
Lackland DT, et al. Evidence-based guideline for the management of high blood pressure in 
Blood Pressure - From Bench to Bed130
adults: Report from the panel members appointed to the eighth Joint National Commitee 
(JNC 8). Journal of the American Medical Association. 2014;311(5):507-520. DOI: 10.1001/
jama.2013.284427
[2] Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascu-
lar diseases: Do we need a more comprehensive strategy? Reviews in Cardiovascular 
Medicine. 2006;7(2):45-54. PMID: 16915123
[3] Pai PY, Muo CH, Sung FC, Ho HC, Lee YT. Angiotensin receptor blockers (ARB) out-
perform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention 
in patients with hypertension and diabetes—A real-world population study in Taiwan. 
International Journal of Cardiology. 2016;215:114-119. DOI: 10.1016/j.ijcard.2016.04.096
[4] Fisher ND, Hollenberg NK. Renin inhibition: What are the therapeutic opportunities? 
Journal of the American Society of Nephrology. 2005;16(3):592-599. DOI: 10.1681/ASN. 
2004100874
[5] Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: Where 
are we now, and where are we going? Journal of Hypertension. 2006;24(2):243-256. DOI: 
10.1097/01.hjh.0000202812.72341.99
[6] Verdecchia P, Calvo C, Möckel V, Keeling L, Satlin A. Safety and efficacy of the oral direct 
renin inhibitor aliskiren in elderly patients with hypertension. Blood Pressure. 2007;16(6):381-
391. DOI: 10.1080/08037050701717014
[7] Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral 
renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. International 
Journal of Clinical Pharmacology and Therapeutics. 2005;43(11):527-535 PMID: 16300168
[8] Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, 
a novel orally effective renin inhibitor, provides dose-dependent antihypertensive effi-
cacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111(8):1012-
1018. DOI: 10.1161/01.CIR.0000156466.02908.ED
[9] Vaidyanathan S, Valencia J, Kemp C, Zhao C, Yeh CM, Bizot MN, et al. Lack of phar-
macokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of 
hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide 
(HCTZ) and ramipril in healthy volunteers. International Journal of Clinical Practice. 
2006;60(11):1343-1356. DOI: 10.1111/j.1742-1241.2006.01164.x
[10] Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, et al. Aliskiren, an 
orally effective renin inhibitor, provides antihypertensive efficacy alone and in combina-
tion with valsartan. American Journal of Hypertension. 2007;20(1):11-20. DOI: 10.1016/j.
amjhyper.2006.06.003
[11] Yarows SA, Oparil S, Patel S, Fang H, Zhang J. Aliskiren and valsartan in stage 2 hyper-
tension: Subgroup analysis of a randomized, double-blind study. Advances in Therapy. 
2008;25(12):1288-1302. DOI: 10.1007/s12325-008-0123-x
Possibilities to Limit the Values of Clinical and Biochemical Parameters in Experimental Arterial Hypertension
http://dx.doi.org/10.5772/intechopen.71689
131
[12] Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-
based therapy lowers blood pressure more effectively than hydrochlorothiazide-based 
therapy in obese patients with hypertension: Sub-analysis of a 52-week, random-
ized, double-blind trial. Journal of Hypertension. 2009;27(7):1493-1501. DOI: 10.1097/
HJH.0b013e32832be593
[13] Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/
prorenin receptor in angiotensin II production and cellular responses to renin. The 
Journal of Clinical Investigation. 2002;109(11):1417-1427. DOI: 10.1172/JCI14276
[14] Krop M, Lu X, Danser AH, Meima ME. The (pro)renin receptor. A decade of research: What 
have we learned? Pflügers Archiv. 2013;465(1):87-97. DOI: 10.1007/s00424-012-1105-z
[15] Holst B, Williamson G. Nutrients and phytochemicals: From bioavailability to bioef-
ficacy beyond antioxidants. Current Opinion in Biotechnology. 2008;19(2):73-82. DOI: 
10.1016/j.copbio.2008.03.003
[16] Davinelli S, Scapagnini G. Polyphenols: A promising nutritional approach to prevent 
or reduce the progression of prehypertension. High Blood Pressure & Cardiovascular 
Prevention. 2016;23(3):197-202. DOI: 10.1007/s40292-016-0149-0
[17] Mohar DS, Malik S. The Sirtuin system: The holy grail of resveratrol? Journal of Clinical 
& Experimental Cardiology. 2012;3(11):216. DOI: 10.4172/2155-9880.1000216
[18] Zhu XY, Daghini E, Chade AR, Rodriguez-Porcel M, Napoli C, Lerman A, et al. Role 
of oxidative stress in remodeling of the myocardial microcirculation in hypertension. 
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(8):1746-1752. DOI: 10.1161/ 
01.ATV.0000227469.40826.01
[19] Naruszewicz M, Laniewska I, Millo B, Dłuzniewski M. Combination therapy of statin 
with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular 
risk markers in patients after myocardial infraction (MI). Atherosclerosis. 2007;194(2):179-
184. DOI: 10.1016/j.atherosclerosis.2006.12.032
[20] Terao J, Kawai Y, Murota K. Vegetable flavonoids and cardiovascular disease. Asia 
Pacific Journal of Clinical Nutrition. 2008;17(1):291-293 PMID: 18296359
[21] Habauzit V, Morand C. Evidence for a protective effect of polyphenols-containing foods 
on cardiovascular health: An update for clinicians. Therapeutic Advances in Chronic 
Disease. 2012;3(2):87-106. DOI: 10.1177/2040622311430006
[22] Skoczynska A, Jedrychowska I, Poreba R, Affelska-Jercha A, Turczyn B, Wojakowska A, 
et al. Influence of chokeberry juice on arterial blood pressure and lipid parameters in 
men with mild hypercholesterolemia. Pharmacology. 2007;59:177-182
[23] Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxi-
dants in normal physiological functions and human disease. The International Journal of 
Biochemistry & Cell Biology. 2007;39(1):44-84. DOI: 10.1016/j.biocel.2006.07.001
Blood Pressure - From Bench to Bed132
[24] Mladenka P, Zatloukalová L, Filipský T, Hrdina R. Cardiovascular effects of flavonoids 
are not caused only by direct antioxidant activity. Free Radical Biology & Medicine. 
2010;49(6):963-975. DOI: 10.1016/j.freeradbiomed.2010.06.010
[25] Sidor A, Gramza-Michałowska A. Advanced research on the antioxidant and health 
benefit of elderberry (Sambucus nigra) in food—A review. Journal of Functional Foods. 
2015;18:941-958. DOI: 10.1016/j.jff.2014.07.012
[26] Mennen LI, Sapinho D, de Bree A, Arnault N, Bertrais S, Galan P, et al. Consumption 
of foods rich in flavonoids is related to a decreased cardiovascular risk in apparently 
healthy French women. The Journal of Nutrition 2004;134(4):923-926. PMID: 15051848
[27] Wu X, Gu L, Prior RL, McKay S. Characterization of anthocyanins and proanthocy-
anidins in some cultivars of Ribes, Aronia, and Sambucus and their antioxidant capac-
ity. Journal of Agricultural and Food Chemistry. 2004;52(26):7846-7856. DOI: 10.1021/
jf0486850
[28] Lee J, Finn CE. Anthocyanins and other polyphenolics in American elderberry (Sambucus 
canadensis) and European elderberry (S. nigra) cultivars. Journal of the Science of Food 
and Agriculture. 2007;87(14):2665-2675. DOI: 10.1002/jsfa.3029
[29] Veberic R, Jakopic J, Stampar F, Schmitzer V. European elderberry (Sambucus nigra L.) 
rich in sugars, organic acids, anthocyanins and selected polyphenols. Food Chemistry. 
2009;114(2):511-515. DOI: 10.1016/j.foodchem.2008.09.080
[30] Gleńsk M, Gliński JA, Włodarczyk M, Stefanowicz P. Determination of ursolic and 
oleanolic acid in Sambuci fructus. Chemistry & Biodiversity. 2014;11(12):1939-1944. DOI: 
10.1002/cbdv.201400118
[31] Salvador ÂC, Rocha SM, Silvestre AJD. Lipophilic phytochemicals from elderberries 
(Sambucus nigra L.): Influence of ripening, cultivar and season. Industrial Crops and 
Products. 2015;71:15-23. DOI: 10.1016/j.indcrop.2015.03.082
[32] Cassidy A, O'Reilly ÉJ, Kay C, Sampson L, Franz M, Forman JP, et al. Habitual intake 
of flavonoid subclasses and incident hypertension in adults. The American Journal of 
Clinical Nutrition. 2011;93(2):338-347. DOI: 10.3945/ajcn.110.006783
[33] Kamata K, Makino A, Kanie N, Oda S, Matsumoto T, Kobayashi T, et al. Effects of antho-
cyanidin derivative (HK-008) on relaxation in rat perfused mesenterial bed. Journal of 
Smooth Muscle Research. 2006;42(2-3):75-88 17001114
[34] Lazzè MC, Pizzala R, Perucca P, Cazzalini O, Savio M, Forti L, et al. Anthocyanidins 
decrease endothelin-1 production and increase endothelial nitric oxide synthase in 
human endothelial cells. Molecular Nutrition & Food Research. 2006;50(1):44-51. DOI: 
10.1002/mnfr.200500134
[35] Ma X, Li YF, Gao Q, Ye ZG, XJ L, Wang HP, et al. Inhibition of superoxide anion-medi-
ated impairment of endothelium by treatment with luteolin and apigenin in rat mesen-
teric artery. Life Sciences. 2008;83(3-4):110-117. DOI: 10.1016/j.lfs.2008.05.010
Possibilities to Limit the Values of Clinical and Biochemical Parameters in Experimental Arterial Hypertension
http://dx.doi.org/10.5772/intechopen.71689
133
[36] Castañeda-Ovando A, Pacheco-Hernández ML, Páez-Hernández ME, Rodríguez JA, 
Galán-Vidal CA. Chemical studies of anthocyanins: A review. Food Chemistry. 2009; 
113(4):859-871. DOI: 10.1016/j.foodchem.2008.09.001
[37] Schini-Kerth VB, Auger C, Kim JH, Etienne-Selloum N, Chataigneau T. Nutritional 
improvement of the endothelial control of vascular tone by polyphenols: Role of NO 
and EDHF. Pflügers Archiv. 2010;459(6):853-862. DOI: 10.1007/s00424-010-0806-4
[38] Wagenfeld L, Himpel O, Galambos P, Matthiesen N, Wiermann A, Richard G, et al. 
Protective effects of nebivolol on oxygen free radical-induced vasoconstrictions in vitro. 
Medical Science Monitor. 2008;14(6):109-112 18509268
[39] Singleton VL, Rossi JA. Colorimetry of total phenolics with phosphomolybdic-phospho-
tungstic acid reagents. American Journal of Enology and Viticulture. 1965;16:144-158
[40] Kawai Y, Nishikawa T, Shiba Y, Saito S, Murota K, Shibata N, et al. Macrophage as a tar-
get of quercetin glucuronides in human atherosclerotic arteries: Implication in the anti-
atherosclerotic mechanism of dietary flavonoids. The Journal of Biological Chemistry. 
2008;283(14):9424-9434. DOI: 10.1074/jbc.M706571200
[41] Feng M, DiPetrillo K. Non-invasive blood pressure measurement in mice. Methods in 
Molecular Biology. 2009;573:45-55. DOI: 10.1007/978-1-60761-247-6_3
[42] Schroeter H, Heiss C, Spencer JP, Keen CL, Lupton JR, Schmitz HH. Recommending fla-
vanols and procyanidins for cardiovascular health: Current knowledge and future needs. 
Molecular Aspects of Medicine. 2010;31(6):546-557. DOI: 10.1016/j.mam.2010.09.008
[43] Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Müller MJ. Serum lipid and 
blood pressure responses to quercetin vary in overweight patients by apolipoprotein 
E genotype. The Journal of Nutrition. 2010;140(2):278-284. DOI: 10.3945/jn.109.117655
[44] Cunha S, Meireles D, Machado J. Sambucus nigra—A promising natural source for 
human health. Experimental Pathology and Health Sciences. 2016;8(2):59-66
[45] Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by 
dietary polyphenols. Biochemical Pharmacology. 2006;72(11):1439-1452. DOI: 10.1016/j.
bcp.2006.07.004
[46] Pascual-Teresa S, Sanchez-Ballesta MT. Anthocyanins: From plant to health. Phyto-
chemistry Reviews. 2008;7(2):281-299. DOI: 10.1007/s11101-007-9074-0
[47] Tsai WC, Huang YY, Lin CC, Li WT, Lee CH, Chen JY, et al. Uric acid is an independent 
predictor of arterial stiffness in hypertensive patients. Heart and Vessels. 2009;24(5):371-
375. DOI: 10.1007/s00380-008-1127-9
[48] Vlachojannis JE, Cameron M, Chrubasik S. A systematic review on the sambuci fructus 
effect and efficacy profiles. Phytotherapy Research. 2010;24(1):1-8. DOI: 10.1002/ptr.2729
[49] Shen G, Hebbar V, Nair S, Xu C, Li W, Lin W, et al. Regulation of Nrf2 transactivation 
domain activity. The differential effects of mitogen-activated protein kinase cascades 
and synergistic stimulatory effect of Raf and CREB-binding protein. The Journal of 
Biological Chemistry. 2004;279(22):23052-23060. DOI: 10.1074/jbc.M401368200
Blood Pressure - From Bench to Bed134
[50] Appeldoorn MM, Venema DP, Peters THF, Koenen ME, Arts ICW, Vincken VP, et al. Some 
phenolic compounds increase the nitric oxide level in endothelial cells in vitro. Journal of 
Agricultural and Food Chemistry. 2009;57(17):7693-7699. DOI: 10.1021/jf901381x
[51] Ghezzi P. Role of glutathione in immunity and inflammation in the lung. International 
Journal of General Medicine. 2011;4:105-113. DOI: 10.2147/IJGM.S15618
[52] Masella R, Di Benedetto R, Varì R, Filesi C, Giovannini C. Novel mechanisms of natural 
antioxidant compounds in biological systems: Involvement of glutathione and glutathi-
one-related enzymes. The Journal of Nutritional Biochemistry. 2005;16(10):577-586. DOI: 
10.1016/j.jnutbio.2005.05.013
[53] Hernandez-Montes E, Pollard SE, Vauzour D, Jofre-Montseny L, Rota C, Rimbach G, 
et al. Activation of glutathione peroxidase via Nrf1 mediates genistein's protec-
tion against oxidative endothelial cell injury. Biochemical and Biophysical Research 
Communications. 2006;346(3):851-859. DOI: 10.1016/j.bbrc.2006.05.197
[54] Tosetti F, Noonan DM, Albini A. Metabolic regulation and redox activity as mecha-
nisms for angioprevention by dietary phytochemicals. International Journal of Cancer. 
2009;125(9):1997-2003. DOI: 10.1002/ijc.24677
[55] Olas B, Wachowicz B, Nowak P, Kedzierska M, Tomczak A, Stochmal A, et al. Studies 
on antioxidant properties of polyphenol-rich extract from berries of Aronia melanocarpa 
in blood platelets. Journal of Physiology and Pharmacology. 2008;59(4):823-835 PMID: 
19212014
[56] Ghosh D, Scheepens A. Vascular action of polyphenols. Molecular Nutrition & Food 
Research. 2009;53(3):322-331. DOI: 10.1002/mnfr.200800182
Possibilities to Limit the Values of Clinical and Biochemical Parameters in Experimental Arterial Hypertension
http://dx.doi.org/10.5772/intechopen.71689
135

